Hypoxia Induced Factor in Chronic Kidney Disease: Friend or Foe?
Many studies have shown evidence that erythropoiesis-stimulating agents (ESAs), as a classic treatment for chronic kidney disease (CKD)-related anemia, have several disadvantages and may trigger various adverse events with long-term use. The hypoxia-induced factor (HIF) pathway has been intensively...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fmed.2017.00259/full |